Analyzing outcomes of neoadjuvant and adjuvant treatment for borderline-resectable pancreatic adenocarcinoma in the perioperative period at an academic institution

BACKGROUND: Only 15–20% of pancreatic ductal adenocarcinoma (PDAC) patients are upfront surgical candidates at presentation, and for this cohort of patients, the 5-year survival is a mere 20% despite adjuvant therapy. Previous data indicate that in clinical practice most of these cases are “borderli...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Ann Pancreat Cancer
Главные авторы: Recio-Boiles, Alejandro, Vondrak, Jessica, Veeravelli, Summana, Mancuso, James J., Saboda, Kathylynn, Roe, Denise J., Riaz, Irbaz Bin, Scott, Aaron J., Elquza, Emad, McBride, Ali, Babiker, Hani M.
Формат: Artigo
Язык:Inglês
Опубликовано: 2020
Предметы:
Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC7170377/
https://ncbi.nlm.nih.gov/pubmed/32313882
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/apc.2020.02.01
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы